Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Ariana Pharmaceuticals

Bio-rad Europe Gmbh

Other

Bio-rad Innovations

Université Paris 7—Denis Diderot

Université René Descartes (paris V)

Inserm

Patrick Marcellin

Tarik Asselah

Isabelle Catherine Batxelli

Nathalie Jullian

Ivan Bieche

Mohammad Afshar

Michel Vidaud

Bénédicte Watelet

Daniel Laune

Eve Laure Mathieu

Eve Mathieu Dupas

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:

Combination of biomarkers for detecting and evaluating a hepatic fibrosis

The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:

Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment

Combination of biomarkers for the detection and evaluation of hepatitis fibrosis

Growing community of inventors

Paris, France

Patrick Marcellin